Abstract 182P
Background
Combining LEN with anti-PD-1 antibodies (LEN+PD1) has shown promising anti-tumour effect against advanced HCC in KEYNOTE 524 and Study 117. We assessed LEN+PD1 vs LEN monotherapy in Chinese patients (Pts) with advanced HCC.
Methods
This real-world study included Pts with untreated advanced HCC who received lenvatinib (8 mg/d regardless of bodyweight) ± anti-PD-1 antibodies (q3wk) between Nov 2018 and Nov 2019, and had ≥1 efficacy and safety assessment. Endpoints included objective response rate (ORR), disease control rate (DCR) and progression free survival (PFS) evaluated using mRECIST and RECIST 1.1 every 2 months from treatment initiation, ALBI score and safety.
Results
The study included 22 patients who received LEN+PD1 and 22 who received LEN. For patients in the LEN+PD1 and LEN groups, median follow-up was 6.6 and 5.3 months, mean age was 54.8 and 53.2 years, 81.8 and 90.9% had BCLC stage C disease, and 72.7 and 68.1% were Child-Pugh A, respectively. ORR and DCR were numerically higher in the LEN+PD1 group vs the LEN group (Table) and median PFS was 12.1 (95% CI: 7.9, 16.2) vs 8.9 months (95% CI: 6.6, 11.2; HR=0.58; 95% CI: 0.17, 1.93), respectively. A similar proportion of patients in both groups decreased one ALBI level from baseline (p=0.9331). The most common AEs in the LEN+PD1 group were hypertension (22.7% [5]), decreased appetite (18.2% [4]) and ALT increase (13.6% [3]) and in the LEN group were ALT increase (31.8% [7]), proteinuria (18.2% [4]) and decreased appetite (18.2% [4]). No unexpected safety signals were observed. Table: 182P
n (%) | RECIST 1.1 | mRECIST | ||||
LEN + PD1 n=22 | LEN n =22 | p | LEN + PD1 n=22 | LEN n =22 | p | |
ORR | 10 (45.5) | 4 (18.2) | 0.052 | 11 (50.0) | 7 (31.8) | 0.220 |
DCR | 20 (90.9) | 17 (77.3) | 0.216 | 20 (90.9) | 17 (77.3) | 0.216 |
Complete response | 1 (4.5) | 0 | 0.204 | 3 (13.6) | 2 (9.1) | 0.526 |
Partial response | 9 (40.9) | 4 (18.2) | 8 (36.4) | 5 (22.7) | ||
Stable disease | 10 (45.5) | 13 (59.1) | 9 (40.9) | 10 (45.5) | ||
Progressive disease | 2 (9.1) | 5 (22.7) | 2 (9.1) | 5 (22.7) |
Conclusions
LEN ± anti-PD-1 antibodies was effective and well tolerated in first-line treatment of patients with advanced HCC. LEN+PD1 showed a trend towards higher ORR, DCR, and longer PFS vs LEN, with no increase in hepatotoxicity. However, further evaluation in randomized, prospective trials is required.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
276P - Sarcopenia to predict overall survival in head and neck cancer patients receiving chemotherapy: A systematic review and meta-analysis
Presenter: Felix Kwenandar
Session: e-Poster Display Session
277P - Tegafur/uracil, platinum and cetuximab (UPEx) as first line treatment in frail patients with recurrent or metastatic head and neck squamous cell carcinoma
Presenter: Meng-che Hsieh
Session: e-Poster Display Session
278P - Serial assessment of parotid volume changes during radical chemoradiation of locally advanced head and neck cancer: Its implications in practice of adaptive radiotherapy
Presenter: Aathira T S
Session: e-Poster Display Session
279P - Clinico pathological characteristics and survival outcome in oral cavity cancer with masticator space involvement (T4b): A retrospective single institutional experience
Presenter: Abdulla Kunnummal Palathinkara
Session: e-Poster Display Session
280P - Safety and efficacy of concurrent chemoradiotherapy for head and neck cancers in younger versus older patients: Post hoc analysis of a randomized control trial
Presenter: Vanita Noronha
Session: e-Poster Display Session
281P - Prevalence of premalignant lesions and oral cancer among tobacco-using tea plantation workers of Nilgiri Hills, Tamilnadu, India
Presenter: Delfin Lovelina Francis
Session: e-Poster Display Session
282P - Filipino head and neck cancer patients and their quality of life
Presenter: Frederic Ivan Ting
Session: e-Poster Display Session
283P - Descriptive epidemiology of head and neck cancer in Niger: First results from the National Cancer Registry
Presenter: Salamatou Mamoudou Garba
Session: e-Poster Display Session
284P - Outcomes of metronomic adjuvant chemotherapy with tegafur-uracil in locally advanced head and neck squamous cell carcinoma
Presenter: Tsung-jang Yeh
Session: e-Poster Display Session
285P - Comparison of induction chemotherapy plus concurrent chemoradiotherapy and concurrent chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma: A meta-analysis
Presenter: Xu Guoqiang
Session: e-Poster Display Session